State Street Corp Boosts Stake in Moderna, Inc. (NASDAQ:MRNA)

State Street Corp boosted its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 12.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,847,212 shares of the company's stock after acquiring an additional 1,823,276 shares during the period. State Street Corp owned 4.38% of Moderna worth $1,125,899,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Simplicity Wealth LLC raised its stake in Moderna by 31.6% during the 2nd quarter. Simplicity Wealth LLC now owns 4,838 shares of the company's stock worth $575,000 after buying an additional 1,161 shares during the period. Czech National Bank raised its holdings in Moderna by 8.9% during the 2nd quarter. Czech National Bank now owns 63,536 shares of the company's stock worth $7,545,000 after buying an additional 5,170 shares during the period. Granite Bay Wealth Management LLC bought a new stake in shares of Moderna during the second quarter worth $524,000. Sequoia Financial Advisors LLC lifted its position in Moderna by 7.1% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 8,722 shares of the company's stock valued at $1,036,000 after acquiring an additional 575 shares in the last quarter. Finally, Wedmont Private Capital boosted its stake in Moderna by 48.4% in the 2nd quarter. Wedmont Private Capital now owns 3,075 shares of the company's stock worth $373,000 after purchasing an additional 1,003 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Up 3.5 %

NASDAQ MRNA traded up $1.50 on Friday, hitting $44.44. 8,735,641 shares of the company were exchanged, compared to its average volume of 10,344,880. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock has a fifty day moving average of $50.27 and a 200-day moving average of $87.86. Moderna, Inc. has a 12 month low of $35.80 and a 12 month high of $170.47. The company has a market cap of $17.10 billion, a PE ratio of -7.64 and a beta of 1.58.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analysts' expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company's revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.39) EPS. As a group, analysts forecast that Moderna, Inc. will post -9.32 earnings per share for the current year.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares of the company's stock, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James M. Mock sold 715 shares of the company's stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares of the company's stock, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,850 shares of company stock valued at $134,560 in the last quarter. 15.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on MRNA shares. Berenberg Bank initiated coverage on Moderna in a research report on Tuesday, November 19th. They set a "hold" rating and a $42.00 price target for the company. Oppenheimer cut Moderna from an "outperform" rating to a "market perform" rating in a research note on Friday, September 13th. Barclays dropped their price target on shares of Moderna from $125.00 to $111.00 and set an "overweight" rating on the stock in a research report on Friday, November 8th. Hsbc Global Res upgraded shares of Moderna from a "hold" rating to a "strong-buy" rating in a research note on Monday, November 18th. Finally, UBS Group reduced their price target on Moderna from $140.00 to $108.00 and set a "buy" rating for the company in a report on Thursday, October 24th. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Moderna currently has a consensus rating of "Hold" and an average price target of $83.33.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.